At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 343 enrolled
Drug / intervention
pregabalin +1 moredrug
Likely dose
pregabalin 450mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 14-week, Randomized, Double-blind Placebo-controlled Study For Pregabalin In Subjects With Fibromyalgia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jul 4, 2011·Updated Jan 28, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin and placebo for Fibromyalgia. Completed, enrolled 343 participants across 22 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and tolerability of pregabalin compared with placebo for management of fibromyalgia in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartFeb 2012
Primary CompletionOct 2016
TodayJul 2026
First PostedJul 4, 2011
Enrollment StartFeb 6, 2012
Primary CompletionOct 31, 2016
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 15.0 years ago
Interventions
pregabalindrug
Pregabalin capsule, 300-450mg/day, twice daily
placebodrug
Placebo, twice daily